Julia Jackowska
Research Subjects
Julia Jackowska has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Agata Mytych
Student Scientific Group of Pediatric Gastroenterology and Nutrition, Wroclaw Medical University, 50-369 Wroclaw, Poland
1 shared publication - Weronika Wrona
Wroclaw Medical University
1 shared publication - Wiktoria Wdowiak
Wroclaw Medical University
1 shared publication - Wiktoria Łuniewska
Lower Silesian Oncology Center, Wroclaw, Poland
1 shared publication
Latest Publications
- Open Access
- 23 December 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (4(48))
OVERVIEW OF MAJOR COMPLICATIONS FOLLOWING HEARTMATE 3 (HM3) LEFT VENTRICULAR ASSIST DEVICE IMPLANTATION
The HeartMate 3 (HM3) left ventricular assist device (LVAD) has become the current standard for mechanical circulatory support in patients with advanced heart failure. Its innovative design, including a fully magnetically levitated rotor and artificial pulse generation, has improved hemocompatibility and reduced mechanical failures. However, device-related complications remain a significant concern affecting patient outcomes. The main side effects of HM3 implantation, such as bleeding, infections, neurological events, and pump thrombosis, are examined in this review along with how they affect survival. Data from major clinical trials and observational studies were examined to identify complication rates, risk factors, and trends over time. Bleeding is the most frequent adverse event, occurring in approximately one-third of patients, with gastrointestinal bleeding observed in nearly 10%. 23–30% of recipients experience infections, especially driveline infections, and 3–5% experience neurological problems like ischaemic and hemorrhagic stroke, usually in the first six months following implantation. Pump thrombosis rates with HM3 remain among the lowest reported, ranging from 1.4% at two years to 2.8% at five years. Long-term results are positive in spite of these difficulties, with survival rates surpassing 80% at two years and 58% at five. Continued refinement of device technology and patient management is essential to further reduce complications and improve overall survival and quality of life.
- 23 December 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (4(48))
Open AccessOVERVIEW OF MAJOR COMPLICATIONS FOLLOWING HEARTMATE 3 (HM3) LEFT VENTRICULAR ASSIST DEVICE IMPLANTATION
The HeartMate 3 (HM3) left ventricular assist device (LVAD) has become the current standard for mechanical circulatory support in patients with advanced heart failure. Its innovative design, including a fully magnetically levitated rotor and artificial pulse generation, has improved hemocompatibility and reduced mechanical failures. However, device-related complications remain a significant concern affecting patient outcomes. The main side effects of HM3 implantation, such as bleeding, infections, neurological events, and pump thrombosis, are examined in this review along with how they affect survival. Data from major clinical trials and observational studies were examined to identify complication rates, risk factors, and trends over time. Bleeding is the most frequent adverse event, occurring in approximately one-third of patients, with gastrointestinal bleeding observed in nearly 10%. 23–30% of recipients experience infections, especially driveline infections, and 3–5% experience neurological problems like ischaemic and hemorrhagic stroke, usually in the first six months following implantation. Pump thrombosis rates with HM3 remain among the lowest reported, ranging from 1.4% at two years to 2.8% at five years. Long-term results are positive in spite of these difficulties, with survival rates surpassing 80% at two years and 58% at five. Continued refinement of device technology and patient management is essential to further reduce complications and improve overall survival and quality of life.